• Covid-19 The first cases of the South African variant of the coronavirus are detected in Galicia and Catalonia

  • Covid-19: British strain teams up with South African mutation to tackle vaccines

  • Madrid.The new tamper cameras at Hospital Isabel Zendal: "Very strange things happen here, it is an orchestrated plan"

  • Covid-19: The hidden face of vaccines: a bomb warning, a deleted tweet and all the prices

Researchers at the University of Oxford have published in

The Lancet Preprints

an analysis of

additional data from ongoing trials of their Covid-19 vaccine

, developed jointly with the pharmaceutical company AstraZeneca.

In addition, the authors give the first clues about the potential of the vaccine to reduce the transmission of the coronavirus: They have observed

a 67 percent reduction in infections

after the first dose in volunteers from their trials in the United Kingdom.

These data are important because, to date, many data have been published on the effectiveness of vaccines in preventing the disease,

but it is still unknown whether they prevent vaccinated people from being infected and contagious in an asymptomatic way.

76% effective from 22 days

On the other hand, in their work they reveal that the efficacy of the vaccine is greater at longer booster intervals, and that a single dose of the vaccine is

76 percent effective from 22 to 90 days

after vaccination.

In this pre-print, which is currently under review by

The Lancet

, they report on an analysis of additional data to include trial information up to December 7, 2020,

which includes a further 201 cases of primary symptomatic Covid-19

(332 cases out of the 131 previously notified).

Thus, they point out that the effect of the dosing interval on efficacy is pronounced, with the efficacy of the vaccine increasing from 54.9 percent with an interval of less than six weeks to 82.4 percent when 12 or more are separated. weeks.

They also detail that a single standard dose of the vaccine is 76 percent effective in protecting against symptomatic Covid-19 during the first 90 days after vaccination, once the immune system has created this protection 22 days after vaccination,

and protection shows little sign of decline in this period.

"Important verification of preliminary data"

"These new data provide important verification of the interim data that was used by more than 25 regulators to grant authorization for the emergency use of the vaccine.

They also support the recommendation to adopt a 12-week booster interval

, as they seek the optimal approach to deployment, and ensures that people are protected from 22 days after a single dose of the vaccine, "said the head of the trials, Professor Andrew Pollard.

Thus, the analyzes presented in this work suggest that it is the dosage interval and not the dosage level that has a great impact on the efficacy of the vaccine.

"This is in line with previous research

supporting greater efficacy with longer priming intervals performed with other vaccines such as influenza, Ebola, and malaria," says Pollard.

The researchers hope to publish data regarding the efficacy of their vaccine in the new virus variants "in the next few days", and they expect the results to be

"very similar to those already reported by other vaccine developers."

According to the criteria of The Trust Project

Know more

  • UK

  • Vaccinations

  • Coronavirus

  • Covid 19

Coronavirus The fight between Brussels and AstraZeneca rises in tone

Coronavirus Vaccination is in danger in 10 autonomous communities due to the failure of the purchase

Coronavirus Margarita Robles asks Jemad for a report of explanations after learning that he has received the first dose of the vaccine

See links of interest

  • Work calendar

  • Coronavirus

  • Andalusia

  • Real Madrid - UCAM Murcia

  • Almeria - Seville